ONCO Share Price Performance
SEK 4.57
3.07 (203.86%)
16.9% undervalued intrinsic discount
SEK 5.50
Fair Value
Price SEK 4.57
AnalystConsensusTarget SEK 5.50
AnalystLowTarget SEK 5.00
AnalystHighTarget SEK 5.50
Fair ValueSEK 5.50
Share Pricen/a
Oncopeptides AB (publ) Stock Price
- 4 Narratives written by author
- 1 Comments on narratives written by author
- 19 Fair Values set on narratives written by author
ONCO Community Narratives
AN
Fair Value SEK 5.5 16.9% undervalued intrinsic discount
EU And Japan Expansion Will Leverage Aging Population Trends
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value SEK 5 8.6% undervalued intrinsic discount
European Pricing And Regulatory Pressures Will Erode Value
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value SEK 5.5 16.9% undervalued intrinsic discount
Aging Population And Precision Oncology Will Open New Markets
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Oncolytics Biotech: A Beacon of Hope in Cancer Treatment
Oncolytics Biotech: A Beacon of Hope in Cancer Treatment In the ever-evolving landscape of oncology, Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) is emerging as a company demonstrating significant promise.Read more
50
users have viewed this narrative0users have liked this narrative
1users have commented on this narrative
4users have followed this narrative
DA
SEK 2.56
78.5% overvalued intrinsic discount
DailyInvestors's Fair Value
Revenue
47.64% p.a.
Profit Margin
19.92%
Future PE
27.43x
Price in 2030
SEK 1.3
European Pricing And Regulatory Pressures Will Erode Value
Key Takeaways Reliance on a single product and tougher regulatory standards heighten financial and operational risks, risking abrupt drops in sales and delayed growth. Competitive pressures, shrinking pricing power, and constrained funding threaten market share, margin stability, and the company's long-term financial health.Read more
10
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
SEK 5
8.6% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
114.41% p.a.
Profit Margin
8.66%
Future PE
36.58x
Price in 2029
SEK 4.06
Aging Population And Precision Oncology Will Open New Markets
Key Takeaways Rapid commercial adoption and efficient operations position Oncopeptides for strong revenue and margin growth, surpassing typical biotech peers. Strategic partnerships, industry trends, and a differentiated product platform create opportunities for immediate cash flow strength and long-term valuation upside.Read more
12
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
SEK 5.5
16.9% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
126.09% p.a.
Profit Margin
12.97%
Future PE
22.91x
Price in 2028
SEK 3.87
EU And Japan Expansion Will Leverage Aging Population Trends
Key Takeaways Accelerating Pepaxti sales, positive market trends, and strict cost controls position the company for sustainable growth and improving margins. Expansion efforts and pipeline development create multiple paths for future revenue and strategic partnerships.Read more
25
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
SEK 5.5
16.9% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
122.78% p.a.
Profit Margin
20.44%
Future PE
14.37x
Price in 2028
SEK 6.34
Trending Discussion
Recently Updated Narratives
DA
Oncolytics Biotech: A Beacon of Hope in Cancer Treatment
Fair Value: SEK 2.56 78.5% overvalued intrinsic discount
4 followersusers have followed this narrative
1 commentusers have commented on this narrative
0 likesusers have liked this narrative
AN
ONCO: NK Cell Platform Progress And Expert Guidance Will Shape Future Risk Reward
Fair Value: SEK 5 8.6% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
ONCO: Improved Profitability And NK Cell Platform Will Drive Long-Term Upside
Fair Value: SEK 5.5 16.9% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Oncopeptides AB (publ) Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -0.98
- 97.88%
- -428.78%
- 1,930.2%
About ONCO
- Founded
- 2000
- Employees
- 75
- CEO
- WebsiteView website
Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. The company’s PDC platform designed with two components, peptide carrier and a cytotoxic payload which utilizes the altered metabolism of cancer cells to hydrolyze PDC into active hydrophilic metabolites, which lead to an enrichment in cancer cells. It offers OPD5, OPDC3, and Gliopep for the treatment of hematological or solid tumors, and glioblastoma. The company also provides Small Polypeptide based Killer Engagers (SPiKE) platform that is designed to bind to both NK-cells and specific targets on various cancer cells. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden.
